Trials / Unknown
UnknownNCT00052156
Vaccine Therapy for Patients With Stage IV Melanoma
A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Plus BCG Versus Placebo Plus BCG as a Post-Surgical Treatment for Stage IV Melanoma
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 670 (planned)
- Sponsor
- CancerVax Corporation · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase III study in patients with melanoma that has spread to the lymph nodes and/or a distant organ, and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CancerVax vaccine (CANVAXIN) |
Timeline
- First posted
- 2003-01-24
- Last updated
- 2005-06-24
Locations
77 sites across 13 countries: United States, Australia, Brazil, Canada, France, Germany, Ireland, Israel, Italy, Netherlands, New Zealand, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00052156. Inclusion in this directory is not an endorsement.